Brind.
  1. Revelation Biosciences is developing innovative solutions for Acute Kidney Injury (AKI), targeting a potential $94 billion market with its Stage 2 and Stage 3 treatments.

Market assessment showed $94B TAM for Gemini.

1 report, 1 independent Updated Aug 6
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Market assessment showed $94B TAM for Gemini.

Who's involved

What this event is mainly about
Gemini

Keep exploring

Part of

Revelation Biosciences is developing innovative solutions for Acute Kidney Injury (AKI), targeting a potential $94 billion market with its Stage 2 and Stage 3 treatments. All 2 developments

The entities involved

  • Gemini

    Chicano rapper

    Nothing else this week.

Coverage

Newest first; wire copies grouped